Shares of Adtalem Global Education are down 18% since the company's "mixed" Q4 results and "disappointing" fiscal 2019 guidance, Piper Jaffray analyst Peter Appert tells investors in a research note. The analyst, who admits Adtalem is a "show-me" story for investors, thinks the company's set-up for the next several years is "compelling." Further, improved nursing starts, which is likely in fiscal Q1 results, will be a key proof-point and catalyst for the shares, Appert writes. He reiterates an Overweight rating on Adtalem Global Education with a $59 price target.